Literature DB >> 27604829

High-Sequence Diversity and Rapid Virus Turnover Contribute to Higher Rates of Coreceptor Switching in Treatment-Experienced Subjects with HIV-1 Viremia.

Rebecca Nedellec1, Joshua T Herbeck2, Peter W Hunt3, Steven G Deeks3, James I Mullins4, Elizabeth D Anton5, Jacqueline D Reeves5, Donald E Mosier1.   

Abstract

Coreceptor switching from CCR5 to CXCR4 is common during chronic HIV-1 infection, but is even more common in individuals who have failed antiretroviral therapy (ART). Prior studies have suggested rapid mutation and/or recombination of HIV-1 envelope (env) genes during coreceptor switching. We compared the functional and genotypic changes in env of viruses from viremic subjects who had failed ART just before and after coreceptor switching and compared those to viruses from matched subjects without coreceptor switching. Analysis of multiple unique functional env clones from each subject revealed extensive diversity at both sample time points and rapid diversification of sequences during the 4-month interval in viruses from both 9 subjects with coreceptor switching and 15 control subjects. Only two subjects had envs with evidence of recombination. Three findings distinguished env clones from subjects with coreceptor switching from controls: (1) lower entry efficiency via CCR5; (2) longer V1/V2 regions; and (3), lower nadir CD4 T cell counts during prior years of infection. Most of these subjects harbored virus with lower replicative capacity associated with protease (PR) and/or reverse transcriptase inhibitor resistance mutations, and the extensive diversification tended to lead either to improved entry efficiency via CCR5 or the gain of entry function via CXCR4. These results suggest that R5X4 or X4 variants emerge from a diverse, low-fitness landscape shaped by chronic infection, multiple ART resistance mutations, the availability of target cells, and reduced entry efficiency via CCR5.

Entities:  

Keywords:  HIV-1 coreceptor switching; sequence diversity; sequence evolution

Mesh:

Substances:

Year:  2016        PMID: 27604829      PMCID: PMC5333564          DOI: 10.1089/AID.2016.0153

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  89 in total

1.  CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection.

Authors:  Christoph G Lange; Hernan Valdez; Kathy Medvik; Robert Asaad; Michael M Lederman
Journal:  Clin Immunol       Date:  2002-02       Impact factor: 3.969

2.  Within-host viral evolution in a heterogeneous environment: insights into the HIV co-receptor switch.

Authors:  S Alizon; B Boldin
Journal:  J Evol Biol       Date:  2010-10-21       Impact factor: 2.411

3.  Bursts of nonsynonymous substitutions in HIV-1 evolution reveal instances of positive selection at conservative protein sites.

Authors:  Georgii A Bazykin; Jonathan Dushoff; Simon A Levin; Alexey S Kondrashov
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-12       Impact factor: 11.205

4.  Frequent intrapatient recombination between human immunodeficiency virus type 1 R5 and X4 envelopes: implications for coreceptor switch.

Authors:  Mattias Mild; Joakim Esbjörnsson; Eva Maria Fenyö; Patrik Medstrand
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

5.  Length polymorphism within the second variable region of the human immunodeficiency virus type 1 envelope glycoprotein affects accessibility of the receptor binding site.

Authors:  D G Fox; P Balfe; C P Palmer; J C May; C Arnold; J A McKeating
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

6.  FastTree 2--approximately maximum-likelihood trees for large alignments.

Authors:  Morgan N Price; Paramvir S Dehal; Adam P Arkin
Journal:  PLoS One       Date:  2010-03-10       Impact factor: 3.240

7.  Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption.

Authors:  Meghan K Rothenberger; Brandon F Keele; Stephen W Wietgrefe; Courtney V Fletcher; Gregory J Beilman; Jeffrey G Chipman; Alexander Khoruts; Jacob D Estes; Jodi Anderson; Samuel P Callisto; Thomas E Schmidt; Ann Thorkelson; Cavan Reilly; Katherine Perkey; Thomas G Reimann; Netanya S Utay; Krystelle Nganou Makamdop; Mario Stevenson; Daniel C Douek; Ashley T Haase; Timothy W Schacker
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-23       Impact factor: 11.205

8.  Drug resistance and viral tropism in HIV-1 subtype C-infected patients in KwaZulu-Natal, South Africa: implications for future treatment options.

Authors:  Ashika Singh; Henry Sunpath; Taryn N Green; Nagavelli Padayachi; Keshni Hiramen; Yolanda Lie; Elizabeth D Anton; Richard Murphy; Jacqueline D Reeves; Daniel R Kuritzkes; Thumbi Ndung'u
Journal:  J Acquir Immune Defic Syndr       Date:  2011-11-01       Impact factor: 3.731

9.  Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.

Authors:  R Wyatt; J Moore; M Accola; E Desjardin; J Robinson; J Sodroski
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

10.  Detection of inferred CCR5- and CXCR4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing.

Authors:  Evelien M Bunnik; Luke C Swenson; Diana Edo-Matas; Wei Huang; Winnie Dong; Arne Frantzell; Christos J Petropoulos; Eoin Coakley; Hanneke Schuitemaker; P Richard Harrigan; Angélique B van 't Wout
Journal:  PLoS Pathog       Date:  2011-06-23       Impact factor: 6.823

View more
  1 in total

1.  HIV tropism switch in archived DNA of HIV-HCV subjects successfully treated with direct-acting antivirals for HCV infection.

Authors:  Monica Basso; Daniela Zago; Renzo Scaggiante; Silvia Cavinato; Irene Pozzetto; Camilla Stagni; Beatrice Parisatto; Anna Maria Cattelan; Giuliana Battagin; Loredana Sarmati; Saverio Giuseppe Parisi
Journal:  Sci Rep       Date:  2021-04-29       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.